中药序贯治疗对NSTAMI患者左心室收缩非同步性影响的研究

目的:研究中药序贯治疗对NSTAMI患者左心室收缩非同步性的改善作用。方法:将入选NSTAMI患者60例随机分为治疗组、对照组各30例。对照组予常规西医治疗,治疗组在对照组治疗基础上,采用中药序贯治疗,先予活血祛瘀之血栓通注射液,而后改用温阳益气之参附针,疗程均为7d,共14d。检测血栓相关指标、心电图及超声检测左心室收缩不同步指数和心功能指标进行评价。结果:治疗组血栓相关指标下降明显优于对照组(P0.05),心电图NST及ΣST改善优于对照组(P0.05),心功能Tei指数、LVEF好转优于对照组(P0.05),左室收缩不同步指数SDI-Tv与SDI-Tmv下降优于对照组(P0.05)。SDI与Tei指数和LVEF呈显著相关性(P0.05),SDI与E/A无相关性(P0.05)。结论:中药序贯治疗能促进NSTAMI的心肌再灌注,有效改善心室收缩不同步运动和心脏功能,无严重不良反应。

Effects of Sequential Treatment of Chinese Drugs on Left Ventricular Asynchrony of NSTAMI Patients

Objective： To study the effect of sequential treatment of Chinese drugs on asynchrony in the left ventricular of NSTAMI patients. Methods： 60 NSTAMI patients were randomized into treatment group （ 30 cases） and control group（ 30 cases） . The control group were givern conventional treatment of Western medicine,while the treatment group,based on the treatment of control group,were treated with sequential use of Chinese drugs,first they were givern Xueshuantong Injection with function of activating blood and removing blood stasis,and then Shenfu Injection with the function of warming yang to supplement qi,each with a treatment course of 7 d,total 14 d. Thrombosis-related indicators,ECG and left ventricular systolic dyssynchrony indicators were detected and cardiac function were evaluated. Results： The thrombosis-related indicators of the treatment group decreased significantly than that of the control group （ P 0. 05） ,the improvement of ECG NST and ΣST,cardiac function Tei index and LVEF of the treatment group is better than that of the control group （ P 0. 05） ,the decline of SDI-Tv and SDI-Tmv of left ventricular systolic dyssynchrony index of the treatment group is better than that of the control group （ P 0. 05） . SDI and Tei index and LVEF were significantly correlated （ P 0. 05） ,SDI and E / A had no correlation （ P 0. 05） . Conclusion： Sequential treatment of Chinese drugs can promote myocardial reperfusion of NSTAMI,improve ventricular asynchrony of contraction and heart function with no serious adverse reactions.